These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 31941080)
21. Transurethral instillation with fusion protein MrpH.FimH induces protective innate immune responses against uropathogenic Escherichia coli and Proteus mirabilis. Habibi M; Asadi Karam MR; Bouzari S APMIS; 2016 Jun; 124(6):444-52. PubMed ID: 26918627 [TBL] [Abstract][Full Text] [Related]
22. Uroplakin Ia is the urothelial receptor for uropathogenic Escherichia coli: evidence from in vitro FimH binding. Zhou G; Mo WJ; Sebbel P; Min G; Neubert TA; Glockshuber R; Wu XR; Sun TT; Kong XP J Cell Sci; 2001 Nov; 114(Pt 22):4095-103. PubMed ID: 11739641 [TBL] [Abstract][Full Text] [Related]
23. Kinetic properties of carbohydrate-lectin interactions: FimH antagonists. Scharenberg M; Jiang X; Pang L; Navarra G; Rabbani S; Binder F; Schwardt O; Ernst B ChemMedChem; 2014 Jan; 9(1):78-83. PubMed ID: 24357503 [TBL] [Abstract][Full Text] [Related]
24. The tyrosine gate as a potential entropic lever in the receptor-binding site of the bacterial adhesin FimH. Wellens A; Lahmann M; Touaibia M; Vaucher J; Oscarson S; Roy R; Remaut H; Bouckaert J Biochemistry; 2012 Jun; 51(24):4790-9. PubMed ID: 22657089 [TBL] [Abstract][Full Text] [Related]
25. Molecular variations in Klebsiella pneumoniae and Escherichia coli FimH affect function and pathogenesis in the urinary tract. Rosen DA; Pinkner JS; Walker JN; Elam JS; Jones JM; Hultgren SJ Infect Immun; 2008 Jul; 76(7):3346-56. PubMed ID: 18474655 [TBL] [Abstract][Full Text] [Related]
26. Curli fimbria: an Escherichia coli adhesin associated with human cystitis. Cordeiro MA; Werle CH; Milanez GP; Yano T Braz J Microbiol; 2016; 47(2):414-6. PubMed ID: 26991275 [TBL] [Abstract][Full Text] [Related]
27. Luteolin decreases the attachment, invasion and cytotoxicity of UPEC in bladder epithelial cells and inhibits UPEC biofilm formation. Shen XF; Ren LB; Teng Y; Zheng S; Yang XL; Guo XJ; Wang XY; Sha KH; Li N; Xu GY; Tian HW; Wang XY; Liu XK; Li J; Huang N Food Chem Toxicol; 2014 Oct; 72():204-11. PubMed ID: 25051393 [TBL] [Abstract][Full Text] [Related]
28. Structural basis of tropism of Escherichia coli to the bladder during urinary tract infection. Hung CS; Bouckaert J; Hung D; Pinkner J; Widberg C; DeFusco A; Auguste CG; Strouse R; Langermann S; Waksman G; Hultgren SJ Mol Microbiol; 2002 May; 44(4):903-15. PubMed ID: 12010488 [TBL] [Abstract][Full Text] [Related]
29. Biocomputational Prediction Approach Targeting FimH by Natural SGLT2 Inhibitors: A Possible Way to Overcome the Uropathogenic Effect of SGLT2 Inhibitor Drugs. Mashraqi MM; Chaturvedi N; Alam Q; Alshamrani S; Bahnass MM; Ahmad K; Alqosaibi AI; Alnamshan MM; Ahmad SS; Beg MMA; Mishra A; Shaikh S; Rizvi SMD Molecules; 2021 Jan; 26(3):. PubMed ID: 33499241 [TBL] [Abstract][Full Text] [Related]
30. The Remarkable Biomechanical Properties of the Type 1 Chaperone-Usher Pilus: A Structural and Molecular Perspective. Hospenthal MK; Waksman G Microbiol Spectr; 2019 Jan; 7(1):. PubMed ID: 30681068 [TBL] [Abstract][Full Text] [Related]
31. Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn's disease. Mydock-McGrane LK; Hannan TJ; Janetka JW Expert Opin Drug Discov; 2017 Jul; 12(7):711-731. PubMed ID: 28506090 [TBL] [Abstract][Full Text] [Related]
32. Compounds targeting YadC of uropathogenic Escherichia coli and its host receptor annexin A2 decrease bacterial colonization in bladder. Li X; Pei G; Zhang L; Cao Y; Wang J; Yu L; Dianjun W; Gao S; Zhang ZS; Yao Z; Wang Q EBioMedicine; 2019 Dec; 50():23-33. PubMed ID: 31757778 [TBL] [Abstract][Full Text] [Related]
33. Incidence of multidrug resistance, pathogenicity island markers, and pathoadaptive FimH mutations in uropathogenic Escherichia coli isolated from asymptomatic hospitalized patients. Ghosh A; Mukherjee M Folia Microbiol (Praha); 2019 Jul; 64(4):587-600. PubMed ID: 30835050 [TBL] [Abstract][Full Text] [Related]
34. Intranasal immunization with fusion protein MrpH·FimH and MPL adjuvant confers protection against urinary tract infections caused by uropathogenic Escherichia coli and Proteus mirabilis. Habibi M; Asadi Karam MR; Shokrgozar MA; Oloomi M; Jafari A; Bouzari S Mol Immunol; 2015 Apr; 64(2):285-94. PubMed ID: 25562574 [TBL] [Abstract][Full Text] [Related]